School of Mathematics and Statistics - Research Publications

Permanent URI for this collection

Search Results

Now showing 1 - 10 of 23
  • Item
    Thumbnail Image
    G protein-linked signaling pathways in bipolar and major depressive disorders.
    Tomita, H ; Ziegler, ME ; Kim, HB ; Evans, SJ ; Choudary, PV ; Li, JZ ; Meng, F ; Dai, M ; Myers, RM ; Neal, CR ; Speed, TP ; Barchas, JD ; Schatzberg, AF ; Watson, SJ ; Akil, H ; Jones, EG ; Bunney, WE ; Vawter, MP (Frontiers Media SA, 2013)
    The G-protein linked signaling system (GPLS) comprises a large number of G-proteins, G protein-coupled receptors (GPCRs), GPCR ligands, and downstream effector molecules. G-proteins interact with both GPCRs and downstream effectors such as cyclic adenosine monophosphate (cAMP), phosphatidylinositols, and ion channels. The GPLS is implicated in the pathophysiology and pharmacology of both major depressive disorder (MDD) and bipolar disorder (BPD). This study evaluated whether GPLS is altered at the transcript level. The gene expression in the dorsolateral prefrontal (DLPFC) and anterior cingulate (ACC) were compared from MDD, BPD, and control subjects using Affymetrix Gene Chips and real time quantitative PCR. High quality brain tissue was used in the study to control for confounding effects of agonal events, tissue pH, RNA integrity, gender, and age. GPLS signaling transcripts were altered especially in the ACC of BPD and MDD subjects. Transcript levels of molecules which repress cAMP activity were increased in BPD and decreased in MDD. Two orphan GPCRs, GPRC5B and GPR37, showed significantly decreased expression levels in MDD, and significantly increased expression levels in BPD. Our results suggest opposite changes in BPD and MDD in the GPLS, "activated" cAMP signaling activity in BPD and "blunted" cAMP signaling activity in MDD. GPRC5B and GPR37 both appear to have behavioral effects, and are also candidate genes for neurodegenerative disorders. In the context of the opposite changes observed in BPD and MDD, these GPCRs warrant further study of their brain effects.
  • Item
    No Preview Available
    A Quartet of PIF bHLH Factors Provides a Transcriptionally Centered Signaling Hub That Regulates Seedling Morphogenesis through Differential Expression-Patterning of Shared Target Genes in Arabidopsis
    Zhang, Y ; Mayba, O ; Pfeiffer, A ; Shi, H ; Tepperman, JM ; Speed, TP ; Quail, PH ; Copenhaver, GP (PUBLIC LIBRARY SCIENCE, 2013-01)
    Dark-grown seedlings exhibit skotomorphogenic development. Genetic and molecular evidence indicates that a quartet of Arabidopsis Phytochrome (phy)-Interacting bHLH Factors (PIF1, 3, 4, and 5) are critically necessary to maintaining this developmental state and that light activation of phy induces a switch to photomorphogenic development by inducing rapid degradation of the PIFs. Here, using integrated ChIP-seq and RNA-seq analyses, we have identified genes that are direct targets of PIF3 transcriptional regulation, exerted by sequence-specific binding to G-box (CACGTG) or PBE-box (CACATG) motifs in the target promoters genome-wide. In addition, expression analysis of selected genes in this set, in all triple pif-mutant combinations, provides evidence that the PIF quartet members collaborate to generate an expression pattern that is the product of a mosaic of differential transcriptional responsiveness of individual genes to the different PIFs and of differential regulatory activity of individual PIFs toward the different genes. Together with prior evidence that all four PIFs can bind to G-boxes, the data suggest that this collective activity may be exerted via shared occupancy of binding sites in target promoters.
  • Item
    No Preview Available
    International network of cancer genome projects
    Hudson, TJ ; Anderson, W ; Aretz, A ; Barker, AD ; Bell, C ; Bernabe, RR ; Bhan, MK ; Calvo, F ; Eerola, I ; Gerhard, DS ; Guttmacher, A ; Guyer, M ; Hemsley, FM ; Jennings, JL ; Kerr, D ; Klatt, P ; Kolar, P ; Kusuda, J ; Lane, DP ; Laplace, F ; Lu, Y ; Nettekoven, G ; Ozenberger, B ; Peterson, J ; Rao, TS ; Remacle, J ; Schafer, AJ ; Shibata, T ; Stratton, MR ; Vockley, JG ; Watanabe, K ; Yang, H ; Yuen, MMF ; Knoppers, M ; Bobrow, M ; Cambon-Thomsen, A ; Dressler, LG ; Dyke, SOM ; Joly, Y ; Kato, K ; Kennedy, KL ; Nicolas, P ; Parker, MJ ; Rial-Sebbag, E ; Romeo-Casabona, CM ; Shaw, KM ; Wallace, S ; Wiesner, GL ; Zeps, N ; Lichter, P ; Biankin, AV ; Chabannon, C ; Chin, L ; Clement, B ; de Alava, E ; Degos, F ; Ferguson, ML ; Geary, P ; Hayes, DN ; Johns, AL ; Nakagawa, H ; Penny, R ; Piris, MA ; Sarin, R ; Scarpa, A ; van de Vijver, M ; Futreal, PA ; Aburatani, H ; Bayes, M ; Bowtell, DDL ; Campbell, PJ ; Estivill, X ; Grimmond, SM ; Gut, I ; Hirst, M ; Lopez-Otin, C ; Majumder, P ; Marra, M ; Ning, Z ; Puente, XS ; Ruan, Y ; Stunnenberg, HG ; Swerdlow, H ; Velculescu, VE ; Wilson, RK ; Xue, HH ; Yang, L ; Spellman, PT ; Bader, GD ; Boutros, PC ; Flicek, P ; Getz, G ; Guigo, R ; Guo, G ; Haussler, D ; Heath, S ; Hubbard, TJ ; Jiang, T ; Jones, SM ; Li, Q ; Lopez-Bigas, N ; Luo, R ; Pearson, JV ; Quesada, V ; Raphael, BJ ; Sander, C ; Speed, TP ; Stuart, JM ; Teague, JW ; Totoki, Y ; Tsunoda, T ; Valencia, A ; Wheeler, DA ; Wu, H ; Zhao, S ; Zhou, G ; Stein, LD ; Lathrop, M ; Ouellette, BFF ; Thomas, G ; Yoshida, T ; Axton, M ; Gunter, C ; McPherson, JD ; Miller, LJ ; Kasprzyk, A ; Zhang, J ; Haider, SA ; Wang, J ; Yung, CK ; Cross, A ; Liang, Y ; Gnaneshan, S ; Guberman, J ; Hsu, J ; Chalmers, DRC ; Hasel, KW ; Kaan, TSH ; Knoppers, BM ; Lowrance, WW ; Masui, T ; Rodriguez, LL ; Vergely, C ; Cloonan, N ; Defazio, A ; Eshleman, JR ; Etemadmoghadam, D ; Gardiner, BA ; Kench, JG ; Sutherland, RL ; Tempero, MA ; Waddell, NJ ; Wilson, PJ ; Gallinger, S ; Tsao, M-S ; Shaw, PA ; Petersen, GM ; Mukhopadhyay, D ; DePinho, RA ; Thayer, S ; Muthuswamy, L ; Shazand, K ; Beck, T ; Sam, M ; Timms, L ; Ballin, V ; Ji, J ; Zhang, X ; Chen, F ; Hu, X ; Yang, Q ; Tian, G ; Zhang, L ; Xing, X ; Li, X ; Zhu, Z ; Yu, Y ; Yu, J ; Tost, J ; Brennan, P ; Holcatova, I ; Zaridze, D ; Brazma, A ; Egevad, L ; Prokhortchouk, E ; Banks, RE ; Uhlen, M ; Viksna, J ; Ponten, F ; Skryabin, K ; Birney, E ; Borg, A ; Borresen-Dale, A-L ; Caldas, C ; Foekens, JA ; Martin, S ; Reis-Filho, JS ; Richardson, AL ; Sotiriou, C ; van't Veer, L ; Birnbaum, D ; Blanche, H ; Boucher, P ; Boyault, S ; Masson-Jacquemier, JD ; Pauporte, I ; Pivot, X ; Vincent-Salomon, A ; Tabone, E ; Theillet, C ; Treilleux, I ; Bioulac-Sage, P ; Decaens, T ; Franco, D ; Gut, M ; Samuel, D ; Zucman-Rossi, J ; Eils, R ; Brors, B ; Korbel, JO ; Korshunov, A ; Landgraf, P ; Lehrach, H ; Pfister, S ; Radlwimmer, B ; Reifenberger, G ; Taylor, MD ; von Kalle, C ; Majumder, PP ; Pederzoli, P ; Lawlor, RT ; Delledonne, M ; Bardelli, A ; Gress, T ; Klimstra, D ; Zamboni, G ; Nakamura, Y ; Miyano, S ; Fujimoto, A ; Campo, E ; de Sanjose, S ; Montserrat, E ; Gonzalez-Diaz, M ; Jares, P ; Himmelbaue, H ; Bea, S ; Aparicio, S ; Easton, DF ; Collins, FS ; Compton, CC ; Lander, ES ; Burke, W ; Green, AR ; Hamilton, SR ; Kallioniemi, OP ; Ley, TJ ; Liu, ET ; Wainwright, BJ (NATURE PORTFOLIO, 2010-04-15)
    The International Cancer Genome Consortium (ICGC) was launched to coordinate large-scale cancer genome studies in tumours from 50 different cancer types and/or subtypes that are of clinical and societal importance across the globe. Systematic studies of more than 25,000 cancer genomes at the genomic, epigenomic and transcriptomic levels will reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies.
  • Item
    Thumbnail Image
    Investigating and Correcting Plasma DNA Sequencing Coverage Bias to Enhance Aneuploidy Discovery
    Chandrananda, D ; Thorne, NP ; Ganesamoorthy, D ; Bruno, DL ; Benjamini, Y ; Speed, TP ; Slater, HR ; Bahlo, M ; Zhou, F (PUBLIC LIBRARY SCIENCE, 2014-01-29)
    Pregnant women carry a mixture of cell-free DNA fragments from self and fetus (non-self) in their circulation. In recent years multiple independent studies have demonstrated the ability to detect fetal trisomies such as trisomy 21, the cause of Down syndrome, by Next-Generation Sequencing of maternal plasma. The current clinical tests based on this approach show very high sensitivity and specificity, although as yet they have not become the standard diagnostic test. Here we describe improvements to the analysis of the sequencing data by reducing GC bias and better handling of the genomic repeats. We show substantial improvements in the sensitivity of the standard trisomy 21 statistical tests, which we measure by artificially reducing read coverage. We also explore the bias stemming from the natural cleavage of plasma DNA by examining DNA motifs and position specific base distributions. We propose a model to correct this fragmentation bias and observe that incorporating this bias does not lead to any further improvements in the detection of fetal trisomy. The improved bias corrections that we demonstrate in this work can be readily adopted into existing fetal trisomy detection protocols and should also lead to improvements in sub-chromosomal copy number variation detection.
  • Item
    Thumbnail Image
    Copy Number Variation in Patients with Disorders of Sex Development Due to 46,XY Gonadal Dysgenesis
    White, S ; Ohnesorg, T ; Notini, A ; Roeszler, K ; Hewitt, J ; Daggag, H ; Smith, C ; Turbitt, E ; Gustin, S ; van den Bergen, J ; Miles, D ; Western, P ; Arboleda, V ; Schumacher, V ; Gordon, L ; Bell, K ; Bengtsson, H ; Speed, T ; Hutson, J ; Warne, G ; Harley, V ; Koopman, P ; Vilain, E ; Sinclair, A ; Orban, L (PUBLIC LIBRARY SCIENCE, 2011-03-07)
    Disorders of sex development (DSD), ranging in severity from mild genital abnormalities to complete sex reversal, represent a major concern for patients and their families. DSD are often due to disruption of the genetic programs that regulate gonad development. Although some genes have been identified in these developmental pathways, the causative mutations have not been identified in more than 50% 46,XY DSD cases. We used the Affymetrix Genome-Wide Human SNP Array 6.0 to analyse copy number variation in 23 individuals with unexplained 46,XY DSD due to gonadal dysgenesis (GD). Here we describe three discrete changes in copy number that are the likely cause of the GD. Firstly, we identified a large duplication on the X chromosome that included DAX1 (NR0B1). Secondly, we identified a rearrangement that appears to affect a novel gonad-specific regulatory region in a known testis gene, SOX9. Surprisingly this patient lacked any signs of campomelic dysplasia, suggesting that the deletion affected expression of SOX9 only in the gonad. Functional analysis of potential SRY binding sites within this deleted region identified five putative enhancers, suggesting that sequences additional to the known SRY-binding TES enhancer influence human testis-specific SOX9 expression. Thirdly, we identified a small deletion immediately downstream of GATA4, supporting a role for GATA4 in gonad development in humans. These CNV analyses give new insights into the pathways involved in human gonad development and dysfunction, and suggest that rearrangements of non-coding sequences disturbing gene regulation may account for significant proportion of DSD cases.
  • Item
    Thumbnail Image
    A High Force of Plasmodium vivax Blood-Stage Infection Drives the Rapid Acquisition of Immunity in Papua New Guinean Children
    Koepfli, C ; Colborn, KL ; Kiniboro, B ; Lin, E ; Speed, TP ; Siba, PM ; Felger, I ; Mueller, I ; McCarthy, JS (PUBLIC LIBRARY SCIENCE, 2013-09)
    BACKGROUND: When both parasite species are co-endemic, Plasmodium vivax incidence peaks in younger children compared to P. falciparum. To identify differences in the number of blood stage infections of these species and its potential link to acquisition of immunity, we have estimated the molecular force of blood-stage infection of P. vivax ((mol)FOB, i.e. the number of genetically distinct blood-stage infections over time), and compared it to previously reported values for P. falciparum. METHODS: P. vivax (mol)FOB was estimated by high resolution genotyping parasites in samples collected over 16 months in a cohort of 264 Papua New Guinean children living in an area highly endemic for P. falciparum and P. vivax. In this cohort, P. vivax episodes decreased three-fold over the age range of 1-4.5 years. RESULTS: On average, children acquired 14.0 new P. vivax blood-stage clones/child/year-at-risk. While the incidence of clinical P. vivax illness was strongly associated with mol FOB (incidence rate ratio (IRR) = 1.99, 95% confidence interval (CI95) [1.80, 2.19]), (mol)FOB did not change with age. The incidence of P. vivax showed a faster decrease with age in children with high (IRR = 0.49, CI95 [0.38, 0.64] p<0.001) compared to those with low exposure (IRR = 0.63, CI95[0.43, 0.93] p = 0.02). CONCLUSION: P. vivax (mol)FOB is considerably higher than P. falciparum (mol)FOB (5.5 clones/child/year-at-risk). The high number of P. vivax clones that infect children in early childhood contribute to the rapid acquisition of immunity against clinical P. vivax malaria.
  • Item
    Thumbnail Image
    Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data
    Loennstedt, IM ; Caramia, F ; Li, J ; Fumagalli, D ; Salgado, R ; Rowan, A ; Salm, M ; Kanu, N ; Savas, P ; Horswell, S ; Gade, S ; Loibl, S ; Neven, P ; Sotiriou, C ; Swanton, C ; Loi, S ; Speed, TP (BMC, 2014)
    Intra-tumor heterogeneity concerns the existence of genetically different subclones within the same tumor. Single sample quantification of heterogeneity relies on precise determination of chromosomal copy numbers throughout the genome, and an assessment of whether identified mutation variant allele fractions match clonal or subclonal copy numbers. We discuss these issues using data from SNP arrays, whole exome sequencing and pathologist purity estimates on several breast cancers characterized by ERBB2 amplification. We show that chromosomal copy numbers can only be estimated from SNP array signals or sequencing depths for subclonal tumor samples with simple subclonal architectures under certain assumptions.
  • Item
    Thumbnail Image
    Comparing somatic mutation-callers: beyond Venn diagrams
    Kim, SY ; Speed, TP (BIOMED CENTRAL LTD, 2013-06-10)
    BACKGROUND: Somatic mutation-calling based on DNA from matched tumor-normal patient samples is one of the key tasks carried by many cancer genome projects. One such large-scale project is The Cancer Genome Atlas (TCGA), which is now routinely compiling catalogs of somatic mutations from hundreds of paired tumor-normal DNA exome-sequence data. Nonetheless, mutation calling is still very challenging. TCGA benchmark studies revealed that even relatively recent mutation callers from major centers showed substantial discrepancies. Evaluation of the mutation callers or understanding the sources of discrepancies is not straightforward, since for most tumor studies, validation data based on independent whole-exome DNA sequencing is not available, only partial validation data for a selected (ascertained) subset of sites. RESULTS: To provide guidelines to comparing outputs from multiple callers, we have analyzed two sets of mutation-calling data from the TCGA benchmark studies and their partial validation data. Various aspects of the mutation-calling outputs were explored to characterize the discrepancies in detail. To assess the performances of multiple callers, we introduce four approaches utilizing the external sequence data to varying degrees, ranging from having independent DNA-seq pairs, RNA-seq for tumor samples only, the original exome-seq pairs only, or none of those. CONCLUSIONS: Our analyses provide guidelines to visualizing and understanding the discrepancies among the outputs from multiple callers. Furthermore, applying the four evaluation approaches to the whole exome data, we illustrate the challenges and highlight the various circumstances that require extra caution in assessing the performances of multiple callers.
  • Item
    Thumbnail Image
    Combining calls from multiple somatic mutation-callers
    Kim, SY ; Jacob, L ; Speed, TP (BMC, 2014-05-21)
    BACKGROUND: Accurate somatic mutation-calling is essential for insightful mutation analyses in cancer studies. Several mutation-callers are publicly available and more are likely to appear. Nonetheless, mutation-calling is still challenging and there is unlikely to be one established caller that systematically outperforms all others. Therefore, fully utilizing multiple callers can be a powerful way to construct a list of final calls for one's research. RESULTS: Using a set of mutations from multiple callers that are impartially validated, we present a statistical approach for building a combined caller, which can be applied to combine calls in a wider dataset generated using a similar protocol. Using the mutation outputs and the validation data from The Cancer Genome Atlas endometrial study (6,746 sites), we demonstrate how to build a statistical model that predicts the probability of each call being a somatic mutation, based on the detection status of multiple callers and a few associated features. CONCLUSION: The approach allows us to build a combined caller across the full range of stringency levels, which outperforms all of the individual callers.
  • Item
    Thumbnail Image
    Estrogenic Plant Extracts Reverse Weight Gain and Fat Accumulation without Causing Mammary Gland or Uterine Proliferation
    Saunier, EF ; Vivar, OI ; Rubenstein, A ; Zhao, X ; Olshansky, M ; Baggett, S ; Staub, RE ; Tagliaferri, M ; Cohen, I ; Speed, TP ; Baxter, JD ; Leitman, DC ; Laudet, V (PUBLIC LIBRARY SCIENCE, 2011-12-07)
    Long-term estrogen deficiency increases the risk of obesity, diabetes and metabolic syndrome in postmenopausal women. Menopausal hormone therapy containing estrogens might prevent these conditions, but its prolonged use increases the risk of breast cancer, as wells as endometrial cancer if used without progestins. Animal studies indicate that beneficial effects of estrogens in adipose tissue and adverse effects on mammary gland and uterus are mediated by estrogen receptor alpha (ERα). One strategy to improve the safety of estrogens to prevent/treat obesity, diabetes and metabolic syndrome is to develop estrogens that act as agonists in adipose tissue, but not in mammary gland and uterus. We considered plant extracts, which have been the source of many pharmaceuticals, as a source of tissue selective estrogens. Extracts from two plants, Glycyrrhiza uralensis (RG) and Pueraria montana var. lobata (RP) bound to ERα, activated ERα responsive reporters, and reversed weight gain and fat accumulation comparable to estradiol in ovariectomized obese mice maintained on a high fat diet. Unlike estradiol, RG and RP did not induce proliferative effects on mammary gland and uterus. Gene expression profiling demonstrated that RG and RP induced estradiol-like regulation of genes in abdominal fat, but not in mammary gland and uterus. The compounds in extracts from RG and RP might constitute a new class of tissue selective estrogens to reverse weight gain, fat accumulation and metabolic syndrome in postmenopausal women.